CO2023013791A2 - Inhibidores terapéuticos de la señalización de gdf15 - Google Patents
Inhibidores terapéuticos de la señalización de gdf15Info
- Publication number
- CO2023013791A2 CO2023013791A2 CONC2023/0013791A CO2023013791A CO2023013791A2 CO 2023013791 A2 CO2023013791 A2 CO 2023013791A2 CO 2023013791 A CO2023013791 A CO 2023013791A CO 2023013791 A2 CO2023013791 A2 CO 2023013791A2
- Authority
- CO
- Colombia
- Prior art keywords
- gdf15
- gfral
- relates
- therapeutic inhibitors
- gdf15 signaling
- Prior art date
Links
- 102000000597 Growth Differentiation Factor 15 Human genes 0.000 title 1
- 108010041834 Growth Differentiation Factor 15 Proteins 0.000 title 1
- 230000011664 signaling Effects 0.000 title 1
- 229940124788 therapeutic inhibitor Drugs 0.000 title 1
- 206010006895 Cachexia Diseases 0.000 abstract 1
- 102100040304 GDNF family receptor alpha-like Human genes 0.000 abstract 1
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 abstract 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 abstract 1
- 101001038371 Homo sapiens GDNF family receptor alpha-like Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 235000018770 reduced food intake Nutrition 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Esta invención se refiere a anticuerpos que se unen a e inhiben la actividad de la proteína receptora similar a alfa de la familia del factor neurotrófico derivado de las células gliales (GFRAL). La invención también se refiere a la ruta de señalización GDF15-GFRAL como una diana terapéutica para estados de caquexia y afecciones que implican una reducción de la toma de alimentos y reducción en la masa muscular y grasa
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2104556.2A GB202104556D0 (en) | 2021-03-31 | 2021-03-31 | Therapeutic inhibitors of GDF15 signalling |
| GBGB2107331.7A GB202107331D0 (en) | 2021-05-21 | 2021-05-21 | Therapeutic inhibitors of GDF15 signalling |
| GBGB2108170.8A GB202108170D0 (en) | 2021-06-08 | 2021-06-08 | Theraputic inhibitors of GDF15 Signalling |
| PCT/EP2022/058669 WO2022207846A1 (en) | 2021-03-31 | 2022-03-31 | Therapeutic inhibitors of gdf15 signalling |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023013791A2 true CO2023013791A2 (es) | 2024-01-25 |
Family
ID=81580347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0013791A CO2023013791A2 (es) | 2021-03-31 | 2023-10-19 | Inhibidores terapéuticos de la señalización de gdf15 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240182585A1 (es) |
| EP (1) | EP4314071A1 (es) |
| JP (1) | JP2024511853A (es) |
| KR (1) | KR20230165285A (es) |
| AU (1) | AU2022251923A1 (es) |
| BR (1) | BR112023020152A2 (es) |
| CA (1) | CA3215737A1 (es) |
| CO (1) | CO2023013791A2 (es) |
| IL (1) | IL307382A (es) |
| MX (1) | MX2023011655A (es) |
| WO (1) | WO2022207846A1 (es) |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| US20050266425A1 (en) | 2003-12-31 | 2005-12-01 | Vaccinex, Inc. | Methods for producing and identifying multispecific antibodies |
| ES2518865T3 (es) | 2004-04-13 | 2014-11-05 | St Vincent's Hospital Sydney Limited | Agente de inhibición de MIC-1 |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| AU2010329847A1 (en) | 2009-12-11 | 2012-07-26 | Genecode As | Methods of facilitating neural cell survival using GDNF family ligand (GFL) mimetics or RET signaling pathway activators |
| WO2013012648A1 (en) | 2011-07-15 | 2013-01-24 | Emory University | Gdf15 in diagnostic and therapeutic applications |
| CN102321173B (zh) | 2011-08-12 | 2013-04-03 | 中国医学科学院肿瘤研究所 | 人源化巨噬细胞抑制因子1单克隆抗体及其应用 |
| SG11201502279YA (en) | 2012-09-26 | 2015-04-29 | Julius Maximilians Universität Würzburg | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15) |
| EP3689370A1 (en) | 2012-12-21 | 2020-08-05 | Aveo Pharmaceuticals Inc. | Anti-gdf15 antibodies |
| PL3653644T3 (pl) | 2014-03-26 | 2024-03-04 | Julius-Maximilians-Universität Würzburg | Przeciwciała monoklonalne przeciwko czynnikowi wzrostu i różnicowania 15 (gdf-15) oraz ich zastosowanie do leczenia kacheksji nowotworowej i nowotworów |
| EP3197493B1 (en) | 2014-09-25 | 2021-03-10 | Aveo Pharmaceuticals Inc. | Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent |
| KR20180054868A (ko) | 2015-10-02 | 2018-05-24 | 율리우스-막시밀리안스 우니버지태트 뷔르츠부르크 | 인간 증식 및 분화 인자 15 (gdf-15)의 저해제와 면역 체크포인트 차단제를 이용한 병용 요법 |
| WO2017121865A1 (en) | 2016-01-15 | 2017-07-20 | Novo Nordisk A/S | Mic-1 receptor and uses thereof |
| WO2017147742A1 (en) | 2016-02-29 | 2017-09-08 | Eli Lilly And Company | Gfral receptor therapies |
| WO2017152105A1 (en) | 2016-03-04 | 2017-09-08 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for modulating body weight |
| SG11201807279QA (en) | 2016-03-31 | 2018-09-27 | Ngm Biopharmaceuticals Inc | Binding proteins and methods of use thereof |
| US11312766B2 (en) | 2016-04-27 | 2022-04-26 | Novartis Ag | Antibodies against growth differentiation factor 15 and uses thereof |
-
2022
- 2022-03-31 WO PCT/EP2022/058669 patent/WO2022207846A1/en active Application Filing
- 2022-03-31 AU AU2022251923A patent/AU2022251923A1/en active Pending
- 2022-03-31 US US18/284,952 patent/US20240182585A1/en active Pending
- 2022-03-31 KR KR1020237037287A patent/KR20230165285A/ko unknown
- 2022-03-31 CA CA3215737A patent/CA3215737A1/en active Pending
- 2022-03-31 EP EP22720935.0A patent/EP4314071A1/en active Pending
- 2022-03-31 BR BR112023020152A patent/BR112023020152A2/pt unknown
- 2022-03-31 MX MX2023011655A patent/MX2023011655A/es unknown
- 2022-03-31 JP JP2023560403A patent/JP2024511853A/ja active Pending
- 2022-03-31 IL IL307382A patent/IL307382A/en unknown
-
2023
- 2023-10-19 CO CONC2023/0013791A patent/CO2023013791A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022207846A1 (en) | 2022-10-06 |
| CA3215737A1 (en) | 2022-10-06 |
| KR20230165285A (ko) | 2023-12-05 |
| BR112023020152A2 (pt) | 2023-11-14 |
| IL307382A (en) | 2023-11-01 |
| MX2023011655A (es) | 2023-10-11 |
| AU2022251923A1 (en) | 2023-11-16 |
| EP4314071A1 (en) | 2024-02-07 |
| US20240182585A1 (en) | 2024-06-06 |
| JP2024511853A (ja) | 2024-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202092668A1 (ru) | Антитела к ил-11 | |
| AR067045A1 (es) | Metodos y composiciones para el tratamiento de enfermedades alergicas | |
| EA202092605A1 (ru) | Антитела к ил-11ra | |
| EA201370081A1 (ru) | Антитела к cd48 и их применение | |
| BR112012033422B8 (pt) | formulação de alimentação por sonda de alimentação diária completa, seu uso e seu método de fabricação | |
| AR115585A1 (es) | Composiciones y métodos para el tratamiento de la infiltración de grasa en músculo | |
| CO6351747A2 (es) | Composicion nutricional para promover desarrollo y crecimiento saludables | |
| MX2019011748A (es) | Anticuerpo biespecífico heterodimérico tipo estructura de anticuerpo natural anti-pd-l1/anti-pd-1 y preparación del mismo. | |
| CL2017001237A1 (es) | Métodos y composiciones para conservar la masa corporal magra y promover la pérdida de grasa durante la pérdida de peso. | |
| EA201290589A1 (ru) | Cd127-связывающие белки | |
| CO2022002622A2 (es) | Anticuerpos anti-cd73 y composiciones | |
| EA201991203A1 (ru) | Способы лечения ожирения антителами к angptl8 | |
| CL2022002963A1 (es) | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas | |
| CO2023013791A2 (es) | Inhibidores terapéuticos de la señalización de gdf15 | |
| EA202091226A1 (ru) | Применение лигниновой фракции в качестве ингредиента пищевой добавки для человека и животных | |
| MX2021007486A (es) | Hidrolizado de colageno para usarse con trastornos de la piel y trastornos intestinales. | |
| BR112022019930A2 (pt) | Dieta para colite ulcerativa, fórmulas, produtos e métodos dos mesmos | |
| EA201990579A1 (ru) | Применение гидролизата коллагена для улучшения способности к выносливости и стимуляции расщепления жиров | |
| GB2564295A (en) | Chromium containing compositions for improving health and fitness | |
| BR112013020913A2 (pt) | tratamento de doença de crohn fistulizante | |
| EA202190504A1 (ru) | Способы лечения псориаза | |
| CO2023000852A2 (es) | Proteína de unión a antígeno | |
| Syed et al. | Andrologic Sequelae in Prostatitis Patients | |
| CO2022015105A2 (es) | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas | |
| ECSP24012819A (es) | Proteínas actrii y usos de las mismas |